Research programme: transmembrane protein modulators - AbCellera/Pfizer

Drug Profile

Research programme: transmembrane protein modulators - AbCellera/Pfizer

Alternative Names: Function-modulating monoclonal antibodies - AbCellera/Pfizer; Monoclonal antibody (mAb) therapeutics - AbCellera/Pfizer

Latest Information Update: 11 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abcellera
  • Developer Abcellera; Pfizer
  • Class Monoclonal antibodies
  • Mechanism of Action Membrane protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 05 Jan 2017 AbCellera Biologics and Pfizer agree to co-develop transmembrane protein modulator antibodies in Canada and USA for undisclosed indications
  • 05 Jan 2017 Early research in Undefined indication in Canada and USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top